Sustained-release preparation containing 5-acetyl-4,6-dimethyl-2[2-[4-(2-methoxyphenyl) piperazinyl]ethylamino] pyrimidine trihydrochloride as active ingredient
US7041317B2 · kind B2 · utility
8Cited by
1References
5Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 22, 2001 |
| Grant date | May 9, 2006 |
| Priority date | — |
| Expiry date | Apr 7, 2023 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/167
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A sustained-release formulation of 5-acetyl-4,6-dimethyl-2-[2-[4-(2-methoxyphenyl)piperazinyl]ethylamino]pyrimidine trihydrochloride coated with a release-controlling film comprising a water-insoluble polymer film having no hydrophilic group. The formulation of the present invention has such a release pattern that the drug release lasts for 20 hours or more, so that can be appropriately administered for treatment. Furthermore, the formulation itself is so stable that its release pattern does not change with pH and the formulation does not suffer from deterioration, coloration and the like with the lapse of time.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.